FDAnews
www.fdanews.com/articles/87139-cv-therapeutics-announces-completion-of-merlin-timi-36-enrollment

CV THERAPEUTICS ANNOUNCES COMPLETION OF MERLIN TIMI-36 ENROLLMENT

May 26, 2006

CV Therapeutics has announced today that patient enrollment in the MERLIN TIMI-36 study of ranolazine is now complete, with over 6,500 patients enrolled. The company expects top line data from the study could be available in the first quarter of 2007.

According to a special protocol assessment (SPA) agreement with FDA, if treatment with Ranexa (ranolazine extended-release tablets) in this study is not associated with an adverse trend in death or arrhythmia compared to placebo, the study's safety database could support potential approval of Ranexa as first-line chronic angina therapy, even if the primary endpoint is not met. In addition, if the primary endpoint is met, Ranexa could potentially also be approved for treatment of acute coronary syndromes (ACS) and secondary prevention.